Survodutide: Side Effects

Safety Overview#

Survodutide (BI 456906) has been evaluated in Phase 2 clinical trials for obesity (COURAGE trial, 387 participants) and MASH (Phase 2b trial, 293 participants). The safety data currently available are derived from these relatively small, shorter-duration studies compared to the extensive Phase 3 programs that support approved medications such as tirzepatide and semaglutide. As survodutide is an investigational compound not yet approved by any regulatory authority, the safety profile described here is based on limited clinical evidence that will be further characterized by the ongoing Phase 3 ACHIEVE program.

The adverse event profile of survodutide is broadly consistent with the class effects of incretin-based therapies, with gastrointestinal events predominating. However, the glucagon receptor component introduces unique pharmacological considerations not present with pure GLP-1 receptor agonists.

Gastrointestinal Adverse Events#

The most frequently reported adverse events with survodutide are gastrointestinal in nature, consistent with the GLP-1 receptor agonist component of its dual mechanism. These events are mediated through GLP-1R activation in the gut and central nervous system, which slows gastric emptying, modulates gut motility, and suppresses appetite.

Nausea is the most commonly reported adverse event, occurring in approximately 30-40% of patients at higher dose levels in Phase 2 trials. The incidence is dose-related, with higher rates observed at the 3.6 mg and 4.8 mg dose levels compared to the 0.6 mg and 2.4 mg groups. Nausea is predominantly mild to moderate in severity, is most common during dose escalation periods, and tends to diminish with continued treatment at a stable dose. Nausea was the most frequent reason for treatment discontinuation in the COURAGE trial.

Diarrhea occurs in approximately 15-25% of patients and is generally mild and self-limiting. The mechanism is related to altered GI motility and fluid secretion associated with incretin receptor activation.

Vomiting is reported in approximately 10-20% of patients depending on the dose level, with higher incidence during dose escalation and at higher maintenance doses. Episodes are usually transient and associated with the nausea that occurs during titration.

Constipation occurs in approximately 8-15% of patients and is attributed to the slowed gastrointestinal transit resulting from GLP-1R activation. It is generally mild and manageable with dietary modifications.

Decreased appetite is reported as a common adverse event and is directly related to the pharmacological mechanism of action. While categorized as an adverse event, reduced appetite contributes to the therapeutic weight loss effect of survodutide. Monitoring for adequate nutritional intake is recommended.

Dose Escalation and Tolerability#

The dose escalation schedule for survodutide was designed to improve gastrointestinal tolerability by allowing gradual adaptation to incretin receptor activation. In the COURAGE trial, survodutide was initiated at 0.6 mg weekly and escalated through intermediate dose steps to the target maintenance doses of 2.4 mg, 3.6 mg, or 4.8 mg weekly. Each escalation step was maintained for a defined period before the next increase.

In the COURAGE trial, treatment discontinuation due to adverse events occurred in approximately 10-15% of patients in the higher-dose groups compared to approximately 4% with placebo. The Phase 3 ACHIEVE program uses optimized dose escalation schedules with more gradual titration designed to further improve gastrointestinal tolerability based on the Phase 2 experience.

The relationship between dose escalation speed and GI adverse event incidence is well established across the incretin therapy class, and gradual titration is critical for patient retention and treatment adherence.

Heart Rate Effects#

Survodutide treatment was associated with modest increases in heart rate of approximately 2-6 beats per minute in Phase 2 trials, consistent with effects observed across the incretin-based therapy class. This heart rate effect is believed to be mediated through GLP-1R activation and is not associated with clinically significant cardiac arrhythmias based on available data. Longer-term cardiovascular monitoring is ongoing in the Phase 3 program.

Pancreatic Enzyme Elevations#

Transient, asymptomatic increases in serum lipase and amylase levels were observed in some survodutide-treated patients in Phase 2 trials. No confirmed cases of clinical pancreatitis were reported in the Phase 2 program. However, pancreatitis is a recognized class concern for GLP-1 receptor agonists, and patients should be monitored for symptoms suggestive of pancreatitis (persistent severe abdominal pain with or without vomiting). The Phase 3 program will further characterize the pancreatic safety profile.

Glucagon-Specific Safety Considerations#

The glucagon receptor agonist component of survodutide introduces pharmacological considerations not present with selective GLP-1 receptor agonists:

Glycemic effects: Glucagon receptor activation stimulates hepatic glycogenolysis and gluconeogenesis, which would be expected to raise blood glucose levels. In survodutide-treated patients, the GLP-1R component's glucose-lowering effect is designed to offset this hyperglycemic tendency. In Phase 2 trials, blood glucose and HbA1c levels remained stable or improved across dose groups, confirming adequate glycemic counterbalance. However, the long-term effects of chronic dual glucagon/GLP-1 receptor stimulation on glucose homeostasis remain to be fully characterized.

Hepatic effects: While glucagon-mediated hepatic lipid oxidation is therapeutically desirable for MASH, chronic glucagon receptor stimulation could theoretically affect other hepatic metabolic pathways. Long-term hepatic safety monitoring is included in the Phase 3 program.

Ketogenesis: Glucagon stimulates hepatic ketone body production. While clinically significant ketoacidosis has not been reported with survodutide, this is a theoretical concern that requires long-term monitoring, particularly in patients with diabetes or conditions that predispose to metabolic acidosis.

Contraindications#

Based on the pharmacological profile and class effects of survodutide's mechanisms of action, the following contraindications apply:

Medullary Thyroid Carcinoma and MEN2#

Survodutide's GLP-1 receptor agonist component activates the same receptor class associated with thyroid C-cell tumors in rodent carcinogenicity studies. While this finding has not been confirmed in humans and its clinical relevance is debated, it represents a class-wide precaution for all GLP-1 receptor agonists. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use survodutide.

Severe Gastrointestinal Disease#

Patients with severe gastrointestinal conditions including gastroparesis, active inflammatory bowel disease, or intestinal obstruction should avoid survodutide. The GLP-1R-mediated delay in gastric emptying and alteration of GI motility could exacerbate these conditions.

Pregnancy#

Based on the class effects of incretin-based therapies and animal reproduction data for related molecules, survodutide should not be used during pregnancy. Given the estimated half-life of approximately 6-7 days, discontinuation well in advance of planned conception would be necessary to ensure adequate washout.

Drug Interactions#

Insulin and Sulfonylureas#

The most clinically relevant drug interaction is the potential for increased hypoglycemia when survodutide is co-administered with insulin or sulfonylureas. Survodutide's GLP-1R component enhances glucose-dependent insulin secretion, and when combined with agents that stimulate insulin release independent of glucose levels, the risk of clinically significant hypoglycemia increases. Dose reduction of concomitant insulin or sulfonylureas should be considered.

Oral Medications Affected by Gastric Emptying#

Survodutide delays gastric emptying through GLP-1R activation, which may alter the absorption rate and bioavailability of orally administered medications. This is particularly relevant for drugs with narrow therapeutic indices, such as warfarin, digoxin, and levothyroxine, where altered absorption kinetics could affect clinical efficacy or safety. Patients taking oral contraceptives should also be aware of potential reduced absorption and consider non-oral contraceptive methods or additional barrier methods.

CYP Enzyme Interactions#

As a peptide therapeutic, survodutide is not expected to undergo clinically meaningful metabolism by CYP enzymes or to inhibit or induce major CYP isoforms. CYP-mediated drug-drug interactions are therefore not anticipated.

Safety Data Limitations#

The current safety profile of survodutide is based on Phase 2 clinical trials involving fewer than 700 total participants, with treatment durations of 46-48 weeks. Several important limitations should be noted:

• Rare adverse events (occurring in fewer than 1% of patients) may not have been detected due to the limited sample size.
• Long-term safety extending beyond one year of treatment is not yet characterized.
• The safety profile in broader populations (elderly, severe renal or hepatic impairment, adolescents) has not been established.
• Cardiovascular outcomes data are not available, and the long-term cardiovascular effects of dual glucagon/GLP-1 receptor agonism are unknown.
• Post-marketing surveillance data do not exist for this investigational compound.

The ongoing Phase 3 ACHIEVE program, with larger patient populations, longer treatment durations, and broader inclusion criteria, will substantially expand the safety database and provide more definitive characterization of the benefit-risk profile.

Related Reading#

• Survodutide overview and research guide
• Survodutide dosing protocols
• Survodutide risks and legal status